Table 2 NCT03634228; NCT03850535, CTR20170975, NCT05012397, NCT01877382) [20,21,26,35,39] reflect ongoing interest in exploring a potential synergistic effect combining MDM2 inhibition with other modalities to enhance therapeutic efficacy and overcome resistance, particularly in hematologic malignancies. The gene discussed is MDM2; the disease is hematologic disorder.